T. Rowe Price Associates
AVDL

T. Rowe Price Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

T. Rowe Price Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,970
Closed -$1.12M – 3139
2025
Q4 		$1.12M Buy
51,970
+3,392
+7% +$65.9K ﹤0.01% 2029
2025
Q3 		$742K Buy
48,578
+3,835
+9% +$49.9K ﹤0.01% 2196
2025
Q2 		$396K Buy
44,743
+4,393
+11% +$38.6K ﹤0.01% 2410
2025
Q1 		$316K Buy
40,350
+3,677
+10% +$30.8K ﹤0.01% 2448
2024
Q4 		$386K Buy
36,673
+6,445
+21% +$78.3K ﹤0.01% 2395
2024
Q3 		$397K Buy
30,228
+837
+3% +$12.8K ﹤0.01% 2349
2024
Q2 		$0 Buy
+29,391
New +$479K ﹤0.01% 2932
2023
Q3 		– Sell
-127,293
Closed -$2.1M – 2894
2023
Q2 		$2.1M Buy
+127,293
New +$1.65M ﹤0.01% 1459
2015
Q2 		– Sell
-1,131,500
Closed -$20.3M – 2539
2015
Q1 		$20.3M Buy
1,131,500
+3,500
+0.3% +$54.8K ﹤0.01% 1130
2014
Q4 		$19.3M Buy
1,128,000
+665,900
+144% +$9.51M ﹤0.01% 1123
2014
Q3 		$6.61M Buy
+462,100
New +$6.64M ﹤0.01% 1410

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates's AVDL Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 51,970 shares — an estimated $1.12M sold.

T. Rowe Price Associates first reported a position in AVDL in Q3 2014 and held it in 11 quarters. The position peaked at $20.3M in Q1 2015. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 51,970 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.12M.
  • T. Rowe Price Associates first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 11 quarters.
  • T. Rowe Price Associates's Avadel Pharmaceuticals position peaked at $20.3M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.